OncoMatch/Clinical Trials/NCT06621563
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Is NCT06621563 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for solid tumors.
Treatment: HS-20117 combined HS-20093 · HS-20117 combined Platinum-containing chemotherapy · HS-20117 combined HS-20093 and 5-FU · HS-20117+CAPEOX · HS-20117+FOLFIRI · HS-20117+mFOLFOX6 — HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MET inhibitor
Any anticancer therapy targeting MET, including TKIs, antibodies or antibody-drug conjugates.
Cannot have received: EGFR-targeted monoclonal or bispecific antibody
Monoclonal or bispecific antibodies targeting EGFR.
Cannot have received: systemic anti-cancer treatment
Systemic anti-cancer treatment (Cytotoxicities and anti-cancer Traditional Chinese medicine or TKIs) within 2 weeks prior to the first dose of HS-20117.
Cannot have received: investigational anti-cancer drugs or antibodies or ADCs
Investigational anti-cancer drugs or antibodies or ADCs within 4 weeks prior to the first dose of HS-20117.
Cannot have received: local radiotherapy
Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117.
Cannot have received: major surgery
Major surgery within 4 weeks prior to the first dose of HS-20117.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify